drug_name event_name drug_id event_id drug_and_event_name
5 Ciprofloxacin Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft 1797513 440276 Ciprofloxacin & Infection AND/OR inflammatory reaction due to internal prosthetic device, implant AND/OR graft 
## Chronograph ##

## Basic demographioc table##
1: DEC cohort n Percentage 2: Drug cohort n Percentage 3: Event cohort n Percentage 4: All drugs cohort n Percentage
Total 36 100 Total 1000 100 Total 196 100 Total 1000 100
Sex gender = FEMALE 23 64 Sex gender = FEMALE 624 62 Sex gender = FEMALE 106 54 Sex gender = FEMALE 603 60
gender = MALE 13 36 gender = MALE 376 38 gender = MALE 90 46 gender = MALE 397 40
Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0 Age (0,20] 0 0
(20,30] 0 0 (20,30] 7 1 (20,30] 0 0 (20,30] 6 1
(30,40] 0 0 (30,40] 22 2 (30,40] 3 2 (30,40] 17 2
(40,50] 3 8 (40,50] 43 4 (40,50] 9 5 (40,50] 34 3
(50,60] 2 6 (50,60] 74 7 (50,60] 8 4 (50,60] 65 6
(60,70] 8 22 (60,70] 242 24 (60,70] 43 22 (60,70] 233 23
(70,80] 15 42 (70,80] 319 32 (70,80] 63 32 (70,80] 367 37
(80,90] 5 14 (80,90] 231 23 (80,90] 53 27 (80,90] 229 23
(90,110] 3 8 (90,110] 62 6 (90,110] 17 9 (90,110] 49 5
Median 72.5 IQR=(66, 80) Median 74 IQR=(67, 82) Median 76 IQR=(68, 84) Median 74 IQR=(68, 81) 
## Gender distribution ##
## DEC vs. drug ##
Characteristic % (n = 36) % (n = 1,000) Std.Diff Characteristic % (n = 36) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 8.3 2.1 -0.28
25 - 29 0 0.7 0.12 Visual system disorder 44.4 34.8 -0.20
30 - 34 0 0.9 0.13 Medical history: Cardiovascular disease
35 - 39 0 1.2 0.16 Atrial fibrillation 52.8 30.0 -0.48
40 - 44 5.6 0.8 -0.27 Cerebrovascular disease 22.2 10.9 -0.31
45 - 49 2.8 2.8 0.00 Coronary arteriosclerosis 58.3 32.6 -0.53
50 - 54 0 3.6 0.27 Heart disease 91.7 59.9 -0.80
55 - 59 5.6 3.8 -0.08 Heart failure 50.0 27.3 -0.48
60 - 64 0 5.2 0.33 Ischemic heart disease 30.6 15.7 -0.36
65 - 69 22.2 16.4 -0.15 Peripheral vascular disease 58.3 30.1 -0.59
70 - 74 22.2 16.7 -0.14 Pulmonary embolism 2.8 4.6 0.10
75 - 79 11.1 15.6 0.13 Venous thrombosis 16.7 6.9 -0.31
80 - 84 13.9 15.2 0.04 Medical history: Neoplasms
85 - 89 8.3 9.0 0.02 Hematologic neoplasm 25.0 8.7 -0.45
90 - 94 8.3 5.0 -0.13 Malignant lymphoma 11.1 3.6 -0.29
95 - 99 0 1.9 0.20 Malignant neoplasm of anorectum 2.8 1.5 -0.09
100 - 104 0 1.2 0.16 Malignant neoplastic disease 55.6 26.1 -0.63
Gender: female 63.9 62.4 -0.03 Malignant tumor of breast 5.6 2.7 -0.14
Medical history: General Malignant tumor of colon 11.1 3.2 -0.31
Acute respiratory disease 52.8 24.0 -0.62 Malignant tumor of lung 13.9 3.0 -0.40
Attention deficit hyperactivity disorder 0 0.9 0.13 Malignant tumor of urinary bladder 5.6 3.0 -0.13
Chronic liver disease 16.7 3.8 -0.43 Medication use
Chronic obstructive lung disease 33.3 11.9 -0.53 Agents acting on the renin-angiotensin system 75.0 69.3 -0.13
Crohn’s disease 2.8 1.1 -0.12 Antibacterials for systemic use 58.3 48.8 -0.19
Dementia 8.3 13.1 0.15 Antidepressants 77.8 61.7 -0.36
Depressive disorder 8.3 12.4 0.13 Antiepileptics 38.9 38.6 -0.01
Diabetes mellitus 86.1 53.8 -0.75 Antiinflammatory and antirheumatic products 47.2 36.1 -0.23
Gastroesophageal reflux disease 13.9 16.2 0.06 Antineoplastic agents 16.7 11.3 -0.16
Gastrointestinal hemorrhage 19.4 6.7 -0.39 Antipsoriatics 0 1.0 0.14
Human immunodeficiency virus infection 0 0.4 0.09 Antithrombotic agents 66.7 49.3 -0.36
Hyperlipidemia 33.3 25.3 -0.18 Beta blocking agents 69.4 62.8 -0.14
Hypertensive disorder 11.1 5.0 -0.23 Calcium channel blockers 69.4 54.3 -0.32
Lesion of liver 19.4 4.4 -0.48 Diuretics 66.7 70.1 0.07
Obesity 5.6 7.6 0.08 Drugs for acid related disorders 44.4 50.4 0.12
Osteoarthritis 58.3 38.1 -0.41 Drugs for obstructive airway diseases 38.9 38.8 0.00
Pneumonia 13.9 5.7 -0.28 Drugs used in diabetes 44.4 53.5 0.18
Psoriasis 0 1.1 0.15 Immunosuppressants 5.6 4.1 -0.07
Renal impairment 75.0 25.4 -1.14 Lipid modifying agents 80.6 71.5 -0.21
Rheumatoid arthritis 11.1 7.0 -0.14 Opioids 47.2 33.1 -0.29
Schizophrenia 16.7 7.7 -0.28 Psycholeptics 63.9 54.6 -0.19
Ulcerative colitis 0 0.4 0.09 Psychostimulants, agents used for adhd and nootropics 19.4 15.5 -0.10
Urinary tract infectious disease 52.8 22.3 -0.66 
## Event vs. All ##
Characteristic % (n = 196) % (n = 1,000) Std.Diff Characteristic % (n = 196) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 4.6 1.4 -0.19
25 - 29 0 0.5 0.10 Visual system disorder 42.9 35.0 -0.16
30 - 34 0.5 0.9 0.05 Medical history: Cardiovascular disease
35 - 39 1.0 0.9 -0.01 Atrial fibrillation 52.6 23.3 -0.63
40 - 44 2.6 0.5 -0.17 Cerebrovascular disease 15.3 8.8 -0.20
45 - 49 2.0 2.3 0.02 Coronary arteriosclerosis 49.5 28.2 -0.45
50 - 54 1.0 2.6 0.12 Heart disease 84.7 55.5 -0.67
55 - 59 2.6 3.9 0.08 Heart failure 49.5 24.0 -0.55
60 - 64 3.6 3.4 -0.01 Ischemic heart disease 25.5 12.6 -0.33
65 - 69 14.3 16.5 0.06 Peripheral vascular disease 43.4 24.3 -0.41
70 - 74 16.8 19.9 0.08 Pulmonary embolism 6.6 1.7 -0.25
75 - 79 13.8 17.2 0.09 Venous thrombosis 16.8 6.3 -0.33
80 - 84 16.8 15.7 -0.03 Medical history: Neoplasms
85 - 89 13.8 9.4 -0.14 Hematologic neoplasm 18.4 8.3 -0.30
90 - 94 4.1 3.5 -0.03 Malignant lymphoma 7.7 4.5 -0.13
95 - 99 6.1 1.7 -0.23 Malignant neoplasm of anorectum 2.6 1.4 -0.08
100 - 104 1.0 1.1 0.01 Malignant neoplastic disease 49.0 26.0 -0.49
Gender: female 54.1 60.3 0.13 Malignant tumor of breast 6.6 3.8 -0.13
Medical history: General Malignant tumor of colon 8.2 3.2 -0.22
Acute respiratory disease 38.8 20.7 -0.40 Malignant tumor of lung 4.1 2.6 -0.08
Attention deficit hyperactivity disorder 1.0 0.3 -0.09 Malignant tumor of urinary bladder 3.1 2.5 -0.03
Chronic liver disease 7.7 2.8 -0.22 Medication use
Chronic obstructive lung disease 21.4 8.1 -0.38 Agents acting on the renin-angiotensin system 45.4 0 -1.29
Crohn’s disease 1.5 1.2 -0.03 Antibacterials for systemic use 39.3 0 -1.14
Dementia 27.0 8.3 -0.51 Antidepressants 42.9 0 -1.22
Depressive disorder 10.2 9.0 -0.04 Antiepileptics 24.0 0 -0.79
Diabetes mellitus 77.6 48.3 -0.64 Antiinflammatory and antirheumatic products 21.9 0 -0.75
Gastroesophageal reflux disease 15.8 14.1 -0.05 Antineoplastic agents 13.3 0 -0.55
Gastrointestinal hemorrhage 9.2 6.9 -0.08 Antipsoriatics 1.0 0 -0.14
Human immunodeficiency virus infection 1.5 0.1 -0.16 Antithrombotic agents 44.4 0 -1.26
Hyperlipidemia 35.7 22.1 -0.30 Beta blocking agents 39.8 0 -1.15
Hypertensive disorder 11.2 4.8 -0.24 Calcium channel blockers 35.7 0 -1.05
Lesion of liver 7.7 2.3 -0.25 Diuretics 43.9 0 -1.25
Obesity 10.2 4.8 -0.21 Drugs for acid related disorders 32.7 0 -0.98
Osteoarthritis 59.2 33.6 -0.53 Drugs for obstructive airway diseases 25.5 0 -0.83
Pneumonia 10.2 4.8 -0.21 Drugs used in diabetes 38.3 0 -1.11
Psoriasis 3.1 1.2 -0.13 Immunosuppressants 2.6 0 -0.23
Renal impairment 51.0 20.7 -0.67 Lipid modifying agents 41.8 0 -1.20
Rheumatoid arthritis 5.6 6.3 0.03 Opioids 32.1 0 -0.97
Schizophrenia 9.2 3.8 -0.22 Psycholeptics 38.8 0 -1.13
Ulcerative colitis 1.5 0.6 -0.09 Psychostimulants, agents used for adhd and nootropics 9.7 0 -0.46
Urinary tract infectious disease 38.8 18.7 -0.45 
## Drug vs. All ##
Characteristic % (n = 196) % (n = 1,000) Std.Diff Characteristic % (n = 196) % (n = 1,000) Std.Diff
Age group Viral hepatitis C 4.6 1.4 -0.19
25 - 29 0 0.5 0.10 Visual system disorder 42.9 35.0 -0.16
30 - 34 0.5 0.9 0.05 Medical history: Cardiovascular disease
35 - 39 1.0 0.9 -0.01 Atrial fibrillation 52.6 23.3 -0.63
40 - 44 2.6 0.5 -0.17 Cerebrovascular disease 15.3 8.8 -0.20
45 - 49 2.0 2.3 0.02 Coronary arteriosclerosis 49.5 28.2 -0.45
50 - 54 1.0 2.6 0.12 Heart disease 84.7 55.5 -0.67
55 - 59 2.6 3.9 0.08 Heart failure 49.5 24.0 -0.55
60 - 64 3.6 3.4 -0.01 Ischemic heart disease 25.5 12.6 -0.33
65 - 69 14.3 16.5 0.06 Peripheral vascular disease 43.4 24.3 -0.41
70 - 74 16.8 19.9 0.08 Pulmonary embolism 6.6 1.7 -0.25
75 - 79 13.8 17.2 0.09 Venous thrombosis 16.8 6.3 -0.33
80 - 84 16.8 15.7 -0.03 Medical history: Neoplasms
85 - 89 13.8 9.4 -0.14 Hematologic neoplasm 18.4 8.3 -0.30
90 - 94 4.1 3.5 -0.03 Malignant lymphoma 7.7 4.5 -0.13
95 - 99 6.1 1.7 -0.23 Malignant neoplasm of anorectum 2.6 1.4 -0.08
100 - 104 1.0 1.1 0.01 Malignant neoplastic disease 49.0 26.0 -0.49
Gender: female 54.1 60.3 0.13 Malignant tumor of breast 6.6 3.8 -0.13
Medical history: General Malignant tumor of colon 8.2 3.2 -0.22
Acute respiratory disease 38.8 20.7 -0.40 Malignant tumor of lung 4.1 2.6 -0.08
Attention deficit hyperactivity disorder 1.0 0.3 -0.09 Malignant tumor of urinary bladder 3.1 2.5 -0.03
Chronic liver disease 7.7 2.8 -0.22 Medication use
Chronic obstructive lung disease 21.4 8.1 -0.38 Agents acting on the renin-angiotensin system 45.4 0 -1.29
Crohn’s disease 1.5 1.2 -0.03 Antibacterials for systemic use 39.3 0 -1.14
Dementia 27.0 8.3 -0.51 Antidepressants 42.9 0 -1.22
Depressive disorder 10.2 9.0 -0.04 Antiepileptics 24.0 0 -0.79
Diabetes mellitus 77.6 48.3 -0.64 Antiinflammatory and antirheumatic products 21.9 0 -0.75
Gastroesophageal reflux disease 15.8 14.1 -0.05 Antineoplastic agents 13.3 0 -0.55
Gastrointestinal hemorrhage 9.2 6.9 -0.08 Antipsoriatics 1.0 0 -0.14
Human immunodeficiency virus infection 1.5 0.1 -0.16 Antithrombotic agents 44.4 0 -1.26
Hyperlipidemia 35.7 22.1 -0.30 Beta blocking agents 39.8 0 -1.15
Hypertensive disorder 11.2 4.8 -0.24 Calcium channel blockers 35.7 0 -1.05
Lesion of liver 7.7 2.3 -0.25 Diuretics 43.9 0 -1.25
Obesity 10.2 4.8 -0.21 Drugs for acid related disorders 32.7 0 -0.98
Osteoarthritis 59.2 33.6 -0.53 Drugs for obstructive airway diseases 25.5 0 -0.83
Pneumonia 10.2 4.8 -0.21 Drugs used in diabetes 38.3 0 -1.11
Psoriasis 3.1 1.2 -0.13 Immunosuppressants 2.6 0 -0.23
Renal impairment 51.0 20.7 -0.67 Lipid modifying agents 41.8 0 -1.20
Rheumatoid arthritis 5.6 6.3 0.03 Opioids 32.1 0 -0.97
Schizophrenia 9.2 3.8 -0.22 Psycholeptics 38.8 0 -1.13
Ulcerative colitis 1.5 0.6 -0.09 Psychostimulants, agents used for adhd and nootropics 9.7 0 -0.46
Urinary tract infectious disease 38.8 18.7 -0.45 
## Top drugs and conditions for DEC ##
drugs_180_days n_180_days
beta blocking agents 50
antithrombotic agents 48
antihistamines for systemic use 36
cardiovascular system 36
alimentary tract and metabolism 35
nervous system 35
stomatological preparations 34
respiratory system 33
all other therapeutic products 32
systemic hormonal preparations, excl. sex hormones and insulins 30
lipid modifying agents 29
lipid modifying agents, plain 29
psychoanaleptics 29
antidepressants 28
antiepileptics 28
blood and blood forming organs 28
agents acting on the renin-angiotensin system 27
analgesics 27
hmg coa reductase inhibitors 27
musculo-skeletal system 26
antiinfectives for systemic use 25
calcium channel blockers 25
dermatologicals 25
other analgesics and antipyretics 25
sensory organs 25
cond_180_days n_180_days
pain 35
pain finding at anatomical site 35
heart disease 33
kidney disease 32
arthropathy 31
diabetes mellitus 31
measurement finding outside reference range 31
pain of truncal structure 31
vascular disorder 31
inflammation of specific body organs 30
inflammation of specific body systems 30
soft tissue lesion 30
abnormal blood cell count 29
type 2 diabetes mellitus 29
measurement finding below reference range 28
anemia 27
cytopenia 27
erythropenia 27
hemoglobin level outside reference range 27
hemoglobin low 27
rbc count abnormal 27
rbc count low 27
renal impairment 27
structural disorder of heart 25
cardiac arrhythmia 24